On April 21, 2026, Biossil Inc. announced the closing of its US$43-million financing round, co-led by Founders Fund and OpenAI. The Toronto-based company is an artificial intelligence drug discovery platform founded to develop targeted therapies for biologically defined patient sub-populations, with a particular focus on offering previously failed drug candidates a chance to advance toward regulatory approval at a fraction of the traditional cost and time. Biossil's platform uses large language models to scavenge through publicly available data from failed clinical trials, identify molecules that may have therapeutic potential in different patient populations or indications, and then buy or license those compounds from their original developers to advance them through new trials. The company is working on treatments for conditions including sickle cell disease, idiopathic pulmonary fibrosis, glioblastoma, breast cancer and Alzheimer's disease. The April 2026 round followed a Founders Fund-led US$22-million financing in 2024 and a 2023 seed financing led by Staircase Ventures. With this round, Biossil's reported valuation exceeded US$100 million and its cumulative equity raised reached approximately US$70 million across all rounds, with additional backers including Modern Capital, Staircase Ventures, Golden Ventures, Panache Ventures, Quiet Capital, 137 Ventures and DRI Healthcare. The proceeds will be used to advance Biossil's pipeline of drug candidates, support ongoing clinical trials across multiple therapeutic areas and continue pursuing licensing agreements with pharmaceutical and biotech partners.